Information Provided By: 
Fly News Breaks for July 5, 2017
SUPN
Jul 5, 2017 | 08:18 EDT
After traveling with Supernus' management, Cantor analyst William Tanner says that the company's SPN-810 and SPN-812 drugs "could possess significant commercial potential as treatments for impulse aggression in ADHD and as a non-stimulant for the treatment of ADHD symptoms, respectively." He thinks that the company's Trokendi XR drug "will continue to gain traction as a prevention for migraine," The analyst raised his price target on the stock to $49 from $34 and keeps a Buy rating on the shares.
News For SUPN From the Last 2 Days
There are no results for your query SUPN
